Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: incobotulinumtoxinA Clear all
Completed Phase 3 Interventional Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

NCT02677805
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo, Botulinum Toxin A - Open Label
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Encinitas, California • Aventura, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin A to Treat Arm Tremor

NCT02207946
View directory record Official record
Conditions
Essential Tremor of the Upper Limbs
Interventions
IncobotulinumtoxinA, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 9:34 PM EDT
Completed No phase listed Observational

Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

NCT01287247
View directory record Official record
Conditions
Cervical Dystonia, Blepharospasm
Interventions
Xeomin®
Biological
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
70
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 22, 2026, 9:34 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids

NCT01583478
View directory record Official record
Conditions
Skin Aging, Elastosis Senilis
Interventions
incobotulinumtoxinA
Biological
Lead sponsor
The Maas Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke

NCT01464307
View directory record Official record
Conditions
Post-stroke Spasticity of the Lower Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Downey, California • Long Beach, California • Fairfield, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

NCT04766723
View directory record Official record
Conditions
Essential Tremor of the Upper Limb
Interventions
NT 201, Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 9:34 PM EDT
Completed No phase listed Observational

Phase IV-Cervical Dystonia-INTEREST IN CD2

NCT01753349
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Elkridge, Maryland • Boston, Massachusetts • Southfield, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Jul 22, 2026, 9:34 PM EDT
Completed No phase listed Observational

Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice

NCT02454803
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Doral, Florida • Chicago, Illinois • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

NCT01392300
View directory record Official record
Conditions
Post-stroke Spasticity of the Upper Limb
Interventions
IncobotulinumtoxinA (400 Units), Placebo Comparator
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Downey, California • Fountain Valley, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting No phase listed Observational

Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents

NCT07267819
View directory record Official record
Conditions
Migraine, Traumatic Brain Injury, Anomalous Health Incidents
Interventions
Xeomin (incobotulinumtoxinA)
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 22, 2026, 9:34 PM EDT
Terminated No phase listed Observational

Longitudinal Evaluation and Real-world Evidence of NT201

NCT05222607
View directory record Official record
Conditions
Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting Phase 2 Interventional

Understanding and Treating Traumatic Brain Injury (TBI) Associated Photophobia With Botulinum Toxin Type A (BoNT-A)

NCT06293300
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
BoNT A
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles

NCT02122536
View directory record Official record
Conditions
Facial Wrinkles
Interventions
Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects, Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects
Drug
Lead sponsor
YMD Eye and Face
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

NCT02419313
View directory record Official record
Conditions
Parkinson, Tremor
Interventions
incobotulinumtoxinA, Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jul 22, 2026, 9:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Retrospective Evaluation of Combination Treatment With the Ulthera System

NCT02444169
View directory record Official record
Conditions
Skin Laxity
Interventions
Ultherapy, Incobotulinumtoxin A, Radiesse, Belotero Balance
Device · Drug
Lead sponsor
Ulthera, Inc
Industry
Eligibility
25 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
5
States / cities
Laguna Beach, California • San Diego, California • Coral Gables, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 22, 2026, 9:34 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Xeomin Treatment of Glabellar Lines Using OLD Versus COLD

NCT05305768
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
IncobotulinumtoxinA
Drug
Lead sponsor
Clinical Testing of Beverly Hills
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Encino, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional

Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients

NCT01968902
View directory record Official record
Conditions
Muscle Spasticity, Multiple Sclerosis
Interventions
incabotulinumtoxinA, Placebo
Biological
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

NCT03806933
View directory record Official record
Conditions
Moderate to Severe Glabellar Frown Lines
Interventions
NT 201
Drug
Lead sponsor
Merz Aesthetics GmbH
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Encino, California • Newport Beach, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700
View directory record Official record
Conditions
Episodic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
46
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Injection for the Management of BPH

NCT00451191
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin type A (BoNT/A)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

NCT05039723
View directory record Official record
Conditions
Photoaging
Interventions
Radiesse, Xeomin, Belotero
Drug
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
22 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy

NCT02002884
View directory record Official record
Conditions
Cerebral Palsy, Spasticity
Interventions
IncobotulinumtoxinA (8 Units per kg body weight), IncobotulinumtoxinA (6 Units per kg body weight), IncobotulinumtoxinA (2 Units per kg body weight)
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting Phase 4 Interventional

Xeomin® and Gait Related Mobility After Stroke

NCT04908423
View directory record Official record
Conditions
Stroke
Interventions
Xeomin®
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
47
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 22, 2026, 9:34 PM EDT